|
|
| |
Clinical Trials
|
Clinical trials are vital to ensuring continued advancement of cancer therapies. ASCO supports access for cancer patients to investigational therapy offered in clinical research studies. For many patients, clinical trials provide the best means for accessing a promising new cancer therapy. However, some insurers deny coverage of routine patient care costs for anyone who enrolls in such trials. ASCO’s long-standing position has been that insurers should cover all routine patient care costs for patients who are enrolled in cancer clinical trials that have been reviewed and approved by one of the following: the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Department of Defense (DoD), the Department of Veterans Affairs (VA), or certain private entities with peer review standards approved by NIH. ASCO also supports the importance of patient enrollment in phase I clinical trials.
|
 |
|
ASCO's Position:
ASCO’s position statement on clinical trials, including information on defining a quality clinical trial, coverage and oversight
|
|
|
Regulations & Regulatory Advocacy:
Regulations, agency letters and other regulatory information
|
|
|
Central Review of Clinical Trials:
ASCO supports centralized review of multi-center clinical trials to improve the consistency and efficiency of clinical trial review. This link provides access to ACSO's policy and ongoing activities related to central review.
|
|
|
|
|
|
|
|
|
|
